March 2, 2022
Astellas Pharma/Seagen’s Padcev (enfortumab vedotin) has inched closer to approval in Europe as the first antibody-drug conjugate (ADC) to treat advanced urothelial cancer in the region, with a key EU panel re-adopting its recommendation after a review of new safety...read more